Acro Biomedical Co (ROCO:6748) Marketable Securities: NT$207.20 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6748 Acro Biomedical Co Ltd ROCO:6748
61 GF Score
Price NT$178.00
GF Value NT$32.20
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Acro Biomedical Co Marketable Securities?

Acro Biomedical Co ROCO:6748 -3.52% 61 Marketable Securities is NT$207.20 Mil as of Dec. 2025. GuruFocus rates ROCO:6748 with a GF Score™ of 61/100 and a GF Value™ of NT$32.20 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Acro Biomedical Co's Marketable Securities for the quarter that ended in Dec. 2025 was NT$207.20 Mil.

Acro Biomedical Co's annual Marketable Securities increased from Dec. 2023 (NT$35.07 Mil) to Dec. 2024 (NT$307.20 Mil) but then declined from Dec. 2024 (NT$307.20 Mil) to Dec. 2025 (NT$207.20 Mil).

Acro Biomedical Co  (ROCO:6748) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Acro Biomedical Co Marketable Securities Related Terms

Acro Biomedical Co Marketable Securities Historical Data

* Premium members only.

The historical data trend for Acro Biomedical Co's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acro Biomedical Co Marketable Securities Chart

Acro Biomedical Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial 30.71 35.01 35.07 307.20 207.20

Acro Biomedical Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.07 27.20 307.20 367.20 207.20
ROCO:6748
61GF Score
Acro Biomedical Co Ltd ROCO:6748
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acro Biomedical Co Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of NT$207.20 Mil mean?
Acro Biomedical Co (ROCO:6748) has a Marketable Securities of NT$207.20 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Acro Biomedical Co and its competitors.
Is Acro Biomedical Co's Marketable Securities too high?
Acro Biomedical Co's current Marketable Securities is NT$207.20 Mil. Overall, Acro Biomedical Co has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Acro Biomedical Co's Marketable Securities compare to VRTX and REGN?
Acro Biomedical Co's Marketable Securities of NT$207.20 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Acro Biomedical Co and its competitors. Acro Biomedical Co's current Marketable Securities is NT$207.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acro Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Acro Biomedical Co (ROCO:6748) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$32.20, compared to a current price of NT$178.00 — trading 452.8% above its estimated fair value. The current Marketable Securities is NT$207.20 Mil. Acro Biomedical Co's overall GF Score™ is 61/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Acro Biomedical Co (ROCO:6748), the current Marketable Securities is NT$207.20 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Acro Biomedical Co (ROCO:6748) Overvalued in 2026?

Based on GuruFocus' analysis, Acro Biomedical Co stock appears to be overvalued. The current stock price of NT$178.00 is trading 452.8% above its estimated GF Value™ of NT$32.20. GuruFocus considers Acro Biomedical Co to be Significantly Overvalued.

Key valuation signals for ROCO:6748:

  • Marketable Securities: NT$207.20 Mil
  • GF Value™: NT$32.20 vs. price of NT$178.00 (452.8% above fair value)
  • GF Score™: 61/100 with 3 warning signs

No single metric tells the full story. See the ROCO:6748 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Acro Biomedical Co Business Description

Address 3rd Floor, No. 57, Luke 2nd Road, Luzhu District, Kaohsiung, TWN
Acro Biomedical Co Ltd is a company whose technical team integrates the Research and development capabilities of Taiwan's major scientific research units and medical centers to jointly develop equipment for repairing organs and tissues in various parts of the human body. It mainly focuses on orthopedics, dentistry, cardiovascular specialists, ophthalmology, surgery, wound care, Medical equipment used in sports injuries and other specialties.
61GF Score

Get the complete analysis for ROCO:6748

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$178.00
Price
NT$32.20
GF Value